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Purpose or Objective: Image-guided intensity modulated 
radiotherapy (IG-IMRT) reduces dose to organs at risk (OARs) 
compared to 3D-conformal radiotherapy (3D-CRT). Currently 
it is not known to what extent this reduces late toxicity in 
prostate cancer patients. We previously reported on 
significant reductions in dose to OARs and acute toxicity. The 
aim of this study was to assess the therapeutic gain with IG-
IMRT in terms of long-term toxicity reductions, and to 
establish to what extent acute toxicity was associated with 
late side effects. For that purpose we used prospective data 
of two randomized trials. 
 
Material and Methods: A total of 242 IG-IMRT patients from a 
hypofractionation trial (2007-2010) and 189 3D-CRT patients 
from a dose escalation trial (1997-2003) with ≥2 completed 
questionnaires were selected. All patients received 78 Gy in 2 
Gy fractions. Applied margins were 10 mm for 3D-CRT and 5-8 
mm for IG-IMRT, all with 0 mm margin towards the rectum 
for the 10 Gy boost. The mean dose to the anorectum was 
34.4 Gy vs. 47.3 Gy, 23.6 Gy vs. 44.6 Gy for the anal canal 
and 33.1 Gy vs. 43.2 Gy for the bladder (all significantly 
reduced with IG-IMRT). Late toxicity was scored using 
identical questionnaires and case report forms according to 
RTOG/EORTC scoring criteria. Study endpoints were grade ≥2 
(G≥2) gastrointestinal (GI) and genitourinary (GU) toxicity. 
Cumulative incidences of G≥2 endpoints were calculated. Cox 
regression was used to determine Relative Risks (RR) for IG-
IMRT, adjusted for baseline factors. RRs of acute toxicity as a 
predictor for late G≥2 endpoints were also calculated. 
 
Results: Median follow-up was 60 months. The five-year (5y) 
cumulative incidence of late G≥2 GI toxicity was 25.4% for IG-
IMRT compared to 36.4% for 3D-CRT (RR=0.62, p=0.009) 
(Figure 1). This resulted from significantly lower incidences 
of increased stool frequency ≥6/day (4.3% vs 16.5%, RR=0.24, 
p<0.001) and non-significant lower incidences of G≥2
(needing medical intervention) rectal bleeding (RR=0.67, 
p=0.4), rectal pain/cramps (RR=0.59, p=0.13), and proctitis 
(RR=0.38, p=0.05). G≥2 anal incontinence (with use of pads) 
was not reduced (RR=1.02, p=0.9). With regard to GU 
toxicity, a non-significant increase was observed with IG-
IMRT with 5y incidences of 46.9% vs. 37.1% for 3D-CRT 
(RR=1.3, p=0.12). Acute toxicity levels G≥2 (mainly proctitis) 
were 29% vs. 51% (p<0.01). Acute GI G≥2 toxicity was 
predictive for late G≥2 toxicity (RR=2.9 for IG -IMRT, 2.5 for 
3D-CRT, both p<0.01), especially for rectal discomfort 
(RR=7.2, p<0.001) in IG-IMRT, and rectal incontinence 
(RR≈3.5, p<0.01) in both groups. IG-IMRT patients with acute 
GU G≥2 complaints had a 1.81 fold (p=0.002) increased risk of 
late GU G≥2 toxicity, compared to 2.37 (p=0.001) for 3D-CRT. 
 
 
 
Conclusion: IG-IMRT for prostate cancer was beneficial since 
it significantly reduced the incidence of long-term GI 
toxicity, as a result of lower doses to OARs and reduced 
acute toxicity levels. GU toxicity was not reduced despite 
significant reductions in bladder dose.  
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Purpose or Objective: To assess outcome and toxicity of 
stereotactic body radiotherapy (SBRT) in prostate cancer 
patients (pts) with recurrent isolated lymph node metastases 
(LNM). 
 
Material and Methods: Between September 2008 and 
December 2014, 40 prostate cancer pts with 47 recurrent 
isolated LNM, were treated with SBRT. Median age was 74 yrs 
(range, 58-83), median Gleason score at the primary 
diagnosis was 7 (range, 5-10). Median and mean time from 
primary treatment to SBRT were 37.45 and 62.6 m, 
respectively (range 11.16–216.03). Diagnosis was performed 
with choline (ch) PET/CT, and the mean and median PSA 
values before SBRT were 5.6 and 4.2 ng/ml, respectively. Six 
(15%) pts were treated in different sessions for metachronous 
metastases, and one (2%) underwent SBRT for two 
synchronous metastases. 21 (52.5%) pts underwent only SBRT, 
remaining 19 (47.5%) received also androgen deprivation 
therapy (ADT). Gross tumor volume (GTV) was delineated 
using choline uptake and planning target volume (PTV) was 
defined as the GTV plus a 5-8 mm isotropic margin. Mean and 
median volume of GTV and PTV were 6.63 cc and 3 cc and 
25.03 and 15.03 cc, respectively. In 90% of cases 5 fractions 
of 6-8 Gy were delivered. Response was assessed with PSA 
evaluation scheduled every 3 m during the first year and then 
every 6 m. Pts with a reduction or a stability of PSA level 
were considered responders. Being evaluation of response 
with ch-PET-CT not mandatory, it was done in 23 (57.5%) pts. 
 
Results: Mean and median follow-up were 30.18 and 23.8 m, 
respectively (range 3.73-79.8). Mean time of biochemical 
progression from the end of SBRT was 15.54 m (range 1.16 - 
48.86), and the 2-years biochemical progression free survival 
(b-PFS) was 44%. We registered a complete concordance 
between PSA increase and progression of disease shown at 
ch-PET/CT. Sixteen (40%) of the pts experienced no disease 
recurrence after SBRT. Of 21 no-ADT pts, 16 (76%) were still 
free from ADT (mean 26.18 m), whereas remaining 5 (24%) 
had a mean deferment time of ADT of 13.58 m. At univariate 
analysis, Gleason score >7 is related with a worse b-PFS 
(p=0.02). Acute grade 2 diarrhea was registered in 1 (2,5%) 
case. Grade 3 small bowel late toxicity was observed in only 
one (2.5%) case 11.76 m after the end of SBRT. 
 
Conclusion: SBRT resulted effective and generally well 
tolerated by pts. PSA level is a valid tool for response 
evaluation and ch-PET/CT can be useful for pts with 
documented biochemical progression. 
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Purpose or Objective: Subtle changes in serum testosterone 
have been noted in prostate cancer patients, without 
androgen blockade, treated with radiotherapy as well as 
radical prostatectomy (RP). The significance of these changes 
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remains unanswered. The aim of the study was to 
retrospectively review the changes in total testosterone in 
low risk prostate cancer patients treated with IMRT alone, in 
comparison with a RP cohort and to assess the correlation 
between dosimetric parameters for the testes and changes in 
the level of testosterone. 
 
Material and Methods: From 2009-2012 we studied 115 men 
in this cross-sectional study. 92 patients underwent RP and 
23 patients were treated with IMRT exclusively. The patients 
were treated with IMRT to the prostate and seminal vesicles 
for a total dose of 76 Gy (2 Gy/d, 5d/w) with 6 MV photons. 
We measured serum levels of total testosterone, at baseline 
and at 3, 12 and 24 months (m) after treatment. We 
calculated the mean and maximum dose in the testes and the 
distance between PTV-testes. T –test and Pearson correlation 
index (PI) were used for statistical purposes. 
 
Results: Patients undergoing RP were younger with IMRT 
(64.3 vs 72 years, p<0.0001). No differences regarding serum 
hormonal levels were found at baseline between the two 
groups. At 3months the testosterone levels were significantly 
lower in IMRT group (360,3 vs 414,83 ng/dl) in comparison 
with RP group (p <0,039). At 12 months testosterone levels 
remained significantly lower (339,89 vs 402,39 ng/dl, p 0,03) 
in the IMRT group. 
In the IMRT group the mean and maximum testes doses (± SD) 
were 0.472Gy (±0.195) and 0.896 Gy (±0.382) respectively. At 
3 months, the mean testosterone reduction was 29.4 ng/dl (± 
111.3), without correlation among the mean and maximum 
dose to the testes (p=0.2). At 12 months, 60% (12/20) of the 
patients had recovered their basal testosterone levels as well 
as 61% (11/18) at 24 months. The PI didn´t show any 
statistical significance related with testosterone kinetics and 
dosimetric parameters at 12 and 24 months. In the 
multivariate analyses, we didn´t find any significant 
relationship regarding: scattered doses in testes; total dose 
to the prostate; distance between PTV-testes or age, with 
testosterone recovery. 
 
Conclusion: Despite IMRT for localized prostate cancer 
leading to low doses to the testes, we observed a decline in 
total testosterone higher than RP. Nevertheless, it doesn´t 
seem to correlate with either dosimetric parameters or the 
scattered dose in testes. More studies are needed to 
elucidate the role that the prostate may play as an endocrine 
organ itself. 
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Purpose or Objective: To investigate the correlation 
between initial prostate volume and the probability of 
developing acute Obstructive Voiding Symptoms (OVS) during 
the course of moderate hypofractionated (HF) prostate RT. 
 
Material and Methods: Data from patients (n=181) 
undergoing IMRT delivered, daily Cone Beam CT guided, HF 
RT were retrospectively analyzed. Two treatment schedules 
were considered: HF1 (2.6 Gy/fr, 27 fr; n=107) and HF2 (3.15 
Gy/fr, 20 fr, 4 days a week; n=74). Patients verifying: 1. 
previous OVS score 3 or greater according the International 
Prostatic Symptoms Score (IPSS), 2. CTVs encompassing 
volume outside the prostatic capsule (i.e. margin for 
extracapsular extension or seminal vesicles invasion), 3. 
presence of central calcification masses or 4. altered RT 
schedules for reasons other than OVS, were excluded. 
Measured HF1 and HF2 median prostate volumes as contoured 
in the simulation CT image were 61.0 cc [18.6, 157.7] and 
53.6 cc [18.5, 114.8], respectively. OVS was assessed 
according the RTOG/CTC v3.0 scale. Development of OVS G2 
or greater during treatment was considered as binary end-
point. Volume-effect correlation was evaluated by logit 
analysis, assuming a log-normal distribution. 
 
Results: OVS G2 or greater was found in HF1 (n=11) and HF2 
(n=10) patients. A few patients HF1 (n=1) and HF2 (n=5) 
needed urethral catheterization. Some patients (n=12) had 
their course of treatment modified due to OVS: temporary 
interruption of treatment (n=6), modified fractionation (n=5), 
urinary catheterization at treatment delivery (n=1). Logit 
analysis showed that prostate volume did not correlate with 
OVS for HF1 patients (p > 0.05) but proved to be significantly 
predictive of OVS for HF2 patients (p = 0.0002). For this 
second arm, normalized gradient of the volume-effect 
regression curve was found to be γ50=7.8 [3.2-14.7] and 
ED50% = 95.7 cc [84.7-117.8] (see Figure). The Receiver 
Operating Characteristics analysis (ROC) showed excellent 
predictive capabilities of the model, with Area Under the 
Curve AUC=0.94. Based on these findings, a volume cutoff 
value of 80 cc, corresponding to an acceptable 20% risk of 
OVS G2 or greater was selected. 
 
 
 
Conclusion: Depending on the HF scheme, patients with 
larger prostate volume will face an increasing risk of OVS. 
This may compromise their quality of life and alter the RT 
treatment schedule. In this work, we successfully correlated 
OVS to prostate volume. This predictive model can be 
exploited for decision-making prior to treatment. In our 
Institution, patients with prostate volume larger than 80 cc 
will be preferably addressed to the HF1 schedule due to the 
risk of OVS. 
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Purpose or Objective: Comorbidity assessment is essential to 
triage of care for men with prostate cancer. Specially in 
these with an expectative of life less of ten years. We made 
a Spanish validation of comorbid revised Charlson index (RCI) 
applied to prostate cancer.  
 
Material and Methods: A group of 619 consecutive patients 
of Prostate Cancer diagnosed between 1994- 2007 were send 
for clinical assessment at Radiation Oncology Department of 
Hospital Clinic of Bacelona. 
A long the period of follow-up ( till November 2014) 69 
patients deceased for Prostate Cancer and were excluded in 
this study in order to determine the risks of mortality 
associated with comorbidities measured by the RCI. 
